Research Article
Autoantibodies to NR2A Peptide of the Glutamate/NMDA Receptor in Patients with Seizure Disorders in Neuropsychiatric Systemic Lupus Erythematosus
Table 3
Comparison of clinical characteristics between patients with seizure and without seizure in NPSLE group.
| | NPSLE | Test value | value | | With seizure () | Without seizure () |
| Number of males/females | 2/15 | 2/17 | 0.014 | 0.906 | Age (years), median (range) | 25 (18 to 51) | 24 (19 to 60) | −0.651 | 0.519 | SLEDAI, median (range) | 22 (16 to 30) | 14 (8 to 19) | 6.571 | | Consciousness disorders, | 12 (71%) | 0 | 20.118 | | ANA (U/mL), median (range) | 175.0 (106.3 to 657.3) | 175.0 (45.8 to 696.9) | 0.499 | 0.621 | Anti-dsDNA (U/mL), median (range) | 233.0 (69.7 to 671.3) | 207.8 (25.6 to 717.5) | −0.068 | 0.946 | Anti-ribosomal P antibodies, | 6 (35%) | 8 (42%) | 0.175 | 0.676 | SSA, | 11 (65%) | 9 (47%) | 1.092 | 0.296 | SSB, | 3 (18%) | 3 (16%) | 0.022 | 0.881 | C3 (g/L), median (range) | 0.32 (0.13 to 1.08) | 0.38 (0.26 to 0.83) | −0.949 | 0.349 | C4 (g/L), median (range) | 0.05 (0.01 to 0.32) | 0.09 (0.05 to 0.33) | −0.691 | 0.494 | Number with/without treatment | 13/4 | 14/5 | | | Users of prednisone (%) | 11 (65%) | 8 (42%) | 1.839 | 0.175 | Dose (mg/day), median (range) | 7.5 (2.5 to 50) | 10 (2.5 to 100) | | | Users of hydroxychloroquine (%) | 9 (53%) | 8 (42%) | 0.423 | 0.516 | Dose (mg/day), median (range) | 400 (150 to 400) | 400 (200 to 400) | | |
|
|